Q1 Earnings Estimate for OCUL Issued By William Blair

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Research analysts at William Blair issued their Q1 2025 earnings estimates for Ocular Therapeutix in a report released on Tuesday, April 8th. William Blair analyst L. Hanbury-Brown forecasts that the biopharmaceutical company will earn ($0.31) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. William Blair also issued estimates for Ocular Therapeutix’s Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.23) EPS and FY2026 earnings at ($1.16) EPS.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

A number of other research firms have also recently issued reports on OCUL. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price target on the stock. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Ocular Therapeutix has an average rating of “Moderate Buy” and an average target price of $16.38.

Ocular Therapeutix Stock Up 10.9 %

Ocular Therapeutix stock opened at $7.11 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The stock has a market capitalization of $1.13 billion, a PE ratio of -5.39 and a beta of 1.49. The business has a 50 day simple moving average of $7.24 and a 200-day simple moving average of $8.58. Ocular Therapeutix has a 12 month low of $4.06 and a 12 month high of $11.78.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in shares of Ocular Therapeutix in the 4th quarter valued at $28,000. Atlas Capital Advisors Inc. acquired a new position in Ocular Therapeutix in the fourth quarter valued at about $43,000. AlphaQuest LLC acquired a new position in Ocular Therapeutix in the fourth quarter valued at about $53,000. GAMMA Investing LLC increased its position in shares of Ocular Therapeutix by 6,760.0% during the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 8,112 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Ocular Therapeutix by 2,045.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 8,446 shares during the last quarter. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Donald Notman sold 6,301 shares of Ocular Therapeutix stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $7.84, for a total transaction of $49,399.84. Following the transaction, the insider now directly owns 204,563 shares in the company, valued at $1,603,773.92. This trade represents a 2.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,895 shares of company stock valued at $283,772 in the last ninety days. 3.50% of the stock is currently owned by corporate insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.